Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects

Overweight Clinical Trial

Official title:

Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of ProbioSatys™ on Weight Reduction in Overweight Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03657186
• Other study ID #: TAR/006118
• Status: Completed
• Phase: N/A
• Start date: August 31, 2018
• Est. completion date: November 28, 2019

Study information

• Verified date: March 2020
• Source: TargEDys
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters in overweight subjects during a 12-week consumption period. In addition, tolerability and safety of ProbioSatys™ will be assessed.

Description:

ProbioSatys™ is a probiotic nutritional solution containing a commensal Enterobacteriaceae food grade strain, Hafnia alvei 4597. The microbiome is known to play a crucial role in body weight management and metabolic disease. ProbioSatys™ mechanism of action relies on bacterial metabolites that send local and central signals via the gut-brain axis by molecularly mimicking satiety hormones involved in appetite regulation.

Numerous ProbioSatys™pre-clinical studies indicate that consumption of the strain leads to body weight loss based on food intake reduction, but also improvement of body composition (increase of lean mass/fat mass ratio), and improvement of glucose metabolism (oral glucose tolerance test, and fasted glycemia).

The present study aims to evaluate the effects of ProbioSatys™ on body weight and related parameters in overweight subjects during a 12-week consumption period. In addition, tolerability and safety of ProbioSatys™ will be assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 236
• Est. completion date: November 28, 2019
• Est. primary completion date: November 28, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. 18 to 65 years old males and females

2. Overweight (Body Mass Index, BMI: 25 kg/m2 - 29.9 kg/m2)

3. Generally in good health

4. Desire to lose weight

5. Regularly consuming 3 main meals/day (breakfast, lunch, dinner)

6. Readiness to comply with study procedures, in particular:

• Follow diet recommendation

• Maintain the habitual level of physical activity during the study

• Fill out the questionnaires and subject diary

• Take the IP as instructed

7. Stable body weight in the last 3 months prior to V1 (=5% self-reported change)

8. Stable concomitant medications (if any) for at least last 3 months prior to V1

9. Women of childbearing potential:

• Negative pregnancy testing (beta HCG-test in urine) at V1

• Women of childbearing potential: commitment to use contraception methods (with the exception of starting new contraception medication)

Participation is based upon written informed consent form by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.

Randomisation criteria (to be checked after run-in at V2):

1. No change in body weight or reduction up to 3 kg (compared to V1)

2. Adequately completed subject diary

3. Readiness and ability to comply with study requirements

4. Relevant inclusion and exclusion criteria met

Exclusion Criteria:

1. Known allergy/sensitivity to any components of the investigational product

2. Pathological electrocardiogram (ECG) at V1

3. History and/or presence of clinically significant self-reported disorder as per investigator's judgement:

• Untreated or non-stabilised thyroid gland disorder

• Untreated or non-stabilised hypertension (regular systolic blood pressure = 140 mmHg and/or diastolic blood pressure = 90 mmHg)

• Digestion/absorption disorders of the gastrointestinal tract (e.g. inflammatory bowel disease, coeliac disease, pancreatitis etc.) and/ or gastrointestinal surgery

• Diabetes mellitus type 1 or untreated/non-stabilised type 2

• Acute or chronic psychotic disorder

• Immunodeficiency

• Any other organ or systemic diseases that could influence the conduct and/or outcome of the study and/or could affect the tolerability of the subject

4. History and/or presence of eating disorders like bulimia, anorexia nervosa, binge-eating as per investigator's judgement

5. Any electronic medical implant

6. Deviation of safety laboratory parameter(s) at V1 that is:

• Clinically significant or

• >2x upper limit of normal, unless the deviation is justified by a previously known not clinically relevant condition (e.g. Gilbert's syndrome)

7. Use of medication/supplementation in the last month prior to V1 and during the study, as per investigator's judgement:

• That could influence gastrointestinal functions (such as antibiotics, probiotics, laxatives, opioids, anticholinergics, anti-diarrheals etc.)

• For weight management (e.g. fat binder/burner, satiety products etc.)

• That could influence body weight (e.g. antidepressants, systemic corticoids etc.)

• That could otherwise interfere with study conduct / evaluation

8. Diet/weight loss programs within the last 3 months prior to V1 and during the study

9. Smoking cessation/modification of smoking level (if any) within 6 months prior to V1 and/or during the study (regular smoking during the study at the same level as prior to the study is allowed)

10. Vegetarian, vegan or other restrictive diet

11. Pregnancy or nursing

12. History of or current abuse of drugs, alcohol or medication

13. Inability to comply with study procedures

14. Participation in another study during the last 30 days prior to V1

15. Any other reason deemed suitable for exclusion, per investigator's judgment

Related Conditions & MeSH terms

• Body Weight
• Overweight
• Weight Loss

Intervention

Dietary Supplement:
• ProbioSatys™
One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.

Other:
• Placebo
One capsule, twice a day, is to be orally taken with 100 mL of water during each breakfast and lunch (approx. 5 minutes after starting eating), total 2 capsules per day.

Locations

Country	Name	City	State
Germany	Analyze & Realize	Berlin
Germany	Barbara Grube	Berlin
Germany	Jörg Förstermann	Berlin

Sponsors (2)

Lead Sponsor	Collaborator
TargEDys	Analyze & Realize

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of adverse events throughout the study		14 weeks
Other	Blood pressure, compared to baseline		4, 8 and 12 weeks
Other	Pulse rate, compared to baseline		4, 8 and 12 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	analysis of full blood count parameters (haemoglobin)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	analysis of full blood count parameters (haematocrit)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	analysis of full blood count parameters (thrombocytes)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	analysis of full blood count parameters (leucocytes)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (alanine transaminase)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (aspartate aminotransferase)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (gamma-glutamyltransferase)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (alkaline phosphatase)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (bilirubin)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (creatinine)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (urea)	14 weeks
Other	Safety laboratory parameters, compared to screening values (V1)	liver and renal function parameters (uric acid)	14 weeks
Other	Global evaluation of tolerability at V5 by subject and the investigator	"very good", "good", "moderate" and "poor"	12 weeks
Other	Gastrointestinal tolerability parameters (Gastrointestinal Symptom Rating Scale questionnaire, GSRS), compared to baseline		4, 8 and 12 weeks
Other	Stool frequency in the week before each visit post- baseline, each compared to the week before baseline (V2)		4, 8 and 12 weeks
Other	Physical activity parameters (Global Physical Activity Questionnaire, GPAQ), compared to baseline		4, 8 and 12 weeks
Primary	Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")		12 weeks
Secondary	Body weight change (in kg), compared to baseline (V2)		4, 8 and 12 weeks
Secondary	Body weight change (%), compared to baseline (V2)		4, 8 and 12 weeks
Secondary	Body weight (in kg )		4, 8 and 12 weeks
Secondary	Proportion of subjects who lost at least 3% of baseline body weight (="3% responders")		4 and 8 weeks
Secondary	Proportion of subjects who lost at least 5% of baseline body weight (="5% responders")		4, 8 and 12 weeks
Secondary	Body fat mass assessed per bioelectrical impedance analysis (BIA), compared to baseline		4, 8 and 12 weeks
Secondary	Body fat free mass assessed per bioelectrical impedance analysis (BIA), compared to baseline		4, 8 and 12 weeks
Secondary	Waist circumference, compared to baseline		4, 8 and 12 weeks
Secondary	Hip circumference, compared to baseline		4, 8 and 12 weeks
Secondary	Lipid metabolism parameters (total cholesterol), compared to screening values (V1)		14 weeks
Secondary	Lipid metabolism parameters (high density lipid cholesterol), compared to screening values (V1)		14 weeks
Secondary	Lipid metabolism parameters (low density lipid cholesterol), compared to screening values (V1)		14 weeks
Secondary	Fasting glucose, compared to screening values (V1)		14 weeks
Secondary	Glycated haemoglobin (HbA1c), compared to screening values (V1)		14 weeks
Secondary	Evaluation of the overall feeling of satiety compared to baseline by using visual analogue scales (VAS)	continuous line between two endpoints: not saturated at all & fully saturated	4, 8 and 12 weeks
Secondary	Evaluation of the overall feeling of fullness compared to baseline by using visual analogue scales (VAS)	continuous line between two endpoints: not full at all & extremely full	4, 8 and 12 weeks
Secondary	Evaluation of the overall feeling of craving compared to baseline by using a 5 point Likert scale	0= "no", 1= "slightly", 2= "moderate", 3= "strong" and 4= "very strong"	4, 8 and 12 weeks
Secondary	General well-being parameters (Impact of Weight on Quality of Life-Lite, IWQOL-LITE), compared to baseline		4, 8 and 12 weeks
Secondary	Global evaluation of benefit at V5 by subject and the investigator	"very good", "good", "moderate" and "poor"	12 weeks